Amphista Enters Protein Degradation Collaborations with Bristol-Myers Squibb and Merck
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 5 (Table of Contents)
Published: 26 May-2022
DOI: 10.3833/pdr.v2022.i5.2691 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Amphista Therapeutics, a biotech focused on the discovery and development of next generation protein degradation therapeutics, has entered into two significant partnerships with pharma giants, Bristol Myers Squibb (BMS) and Merck KGaA...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS